Bram Vanparys

Bram Vanparys

Bram Vanparys

Managing Partner – Head Life Sciences - Gimv

Bram Vanparys joined Gimv in 2018 and has over 15 years of international venture capital experience.

Bram has a successful track record in Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe and Israel, including arGEN-X (ARGX:EBR), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent), Q-Biologicals (acquired by Amatsigroup, now Eurofins), Calypso Biotech and iOmx.

Today, Bram acts as a board member for portfolio companies ImCheck Therapeutics (France), iSTAR Medical (Belgium), Kinaset Therapeutics (US), Topas Therapeutics (Germany) and Anjarium (Switzerland).

Bram is trained as a PhD in biotechnology (University of Ghent, Belgium) and has an executive MBA from Vlerick Business School (Belgium).

Registrations are now open!

KNOWLEDGE FOR GROWTH Institutional Partners

KNOWLEDGE FOR GROWTH Supporting Partners

FLANDERS.BIO Strategic Partners